清下消补法组方对乙肝肝硬化预后因素影响的研究

Effect of Qingxia Xiaobu Prescription on Prognosis of Hepatitis B Cirrhosis

目的探讨清下消补法组方对乙肝肝硬化预后因素的影响。方法方便抽取2015年8月—2017年7月该院收治的72例乙肝肝硬化患者,运用随机数字表法将其分为对照组(n=36)与实验组(n=36),对照组予以复方甘草酸苷胶囊治疗,实验组予以清下消补法组方治疗,观察两组患者治疗前后TBIL、ALB、PT、Hb及实验组治疗前后的TBIL、ALB、PT、Hb指标变化情况。结果经治疗后,实验组血清总胆红素(TBIL)为(42.07±30.63)μmol/L,改变程度优于对照组(62.81±42.95)μmol/L,差异有统计学意义(t=5.359,P<0.05),血清白蛋白(ALB)与凝血酶原时间(PT)、血红蛋白(Hb)在治疗前后组间比较差异无统计学意义(t1=0.583、0.284、0.266,P>0.05;t2=0.597、0.547、0.570,P>0.05)。结论 TBIL是影响乙肝肝硬化预后的主要因素,使用清下消补法组方能够有效的降低患者的TBIL水平,具有较高的临床推广价值。

Objective To investigate the effect of Qingxia Xiaobu prescription on the prognosis of hepatitis B cirrhosis.Methods 72 hepatitis B patients with liver cirrhosis who were admitted to the hospital from August 2015 to July 2017 were convenient selected and randomly divided into a control group（n=36） and an experimental group（n=36）. After treatment with compound glycyrrhizin capsules, the experimental group was treated with Qingxia Xiaobu prescription and the changes of TBIL, ALB, PT, and Hb before and after treatment in the TBIL, ALB, PT, and Hb groups before and after treatment were observed. Results After treatment, serum total bilirubin（TBIL） was（42.07±30.63）μmol/L in the experimental group, and the change was better than that in the control group（62.81±42.95） μmol/L. The difference was statistically significant（t=5.359,P〈0.05）, serum albumin（ALB）, prothrombin time（PT）, and hemoglobin（Hb） had no significant difference before and after treatment（t1=0.583, 0.284, 0.266, P〉0.05; after treatment, t2=0.597, 0.547, 0.570, P〉0.05）. Conclusion TBIL is the main factor affecting the prognosis of HBV cirrhosis. The use of Qingxia Replenishment Method can effectively reduce the TBIL level in patients with high TBIL.